Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ADA 2025: Tandem Becomes Abbott’s Fourth Partner In Push To Advance Dual Sensor CGM Strategy

Jun 23 2025

• By Marion Webb

(Shutterstock)

Related Content

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

May 29 2025

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

May 27 2025

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

May 23 2025

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

May 15 2025

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

May 06 2025

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

May 06 2025

Abbott Embeds Libre Glucose Data In Epic EHR, Expanding Digital Health Footprint

May 01 2025

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

Apr 22 2025

Dexcom Promotes CGM As First-Line Tool In Type 2 Diabetes

Apr 15 2025

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

Apr 10 2025

Dexcom’s FDA Warning Letter Shows Risks Of Driving Margin As Firm Aims To Launch 15-Day Sensor

Apr 04 2025

Dexcom’s Jake Leach And Adrian Gut Discuss Strategy For CGM Growth, Reimbursement, AI Integration And Policy Challenges

Apr 02 2025

Dexcom Faces US FDA Warning Amid Agency Review Of 15-Day Sensor

Mar 17 2025

More from Strategy

More from Digital Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window